New share issue in Biovitrum AB (publ)

In  accordance  with  Biovitrum  stock  option  program  2006:2   TO3
2006/2008, 250 502 new shares have been issued at the price SEK 59.00
per share, resulting in Biovitrum being provided funds of a total  of
SEK 14  779 618.00.  No stock  options  remain in  the  stock  option
program 2006:2 TO3 2006/2008.

After the share issue the  outstanding number of shares in  Biovitrum
is 46 015 624.

For more information please contact:
Biovitrum
Göran Arvidson, CFO
Phone: +46 8 697 23 68

Erik Kinnman, VP Investor Relations
Phone: +46 8 697 21 50
erik.kinnman@biovitrum.com


About Biovitrum
Biovitrum is a pharmaceutical company  with operations in Sweden  and
in the UK. The company markets a range of specialist  pharmaceuticals
primarily in the Nordic countries. Using its expertise and experience
Biovitrum takes scientific innovation all  the way to the market  and
to specialist  indication  patients with  significant  medical  need.
Research  expertise   and   capabilities  include   development   and
production of biotechnology therapeutics,  as well as small  molecule
discovery and  development. With  revenues of  approximately SEK  1.3
billion and around 500 employees, Biovitrum is a significant European
specialty pharmaceutical  player.  It is  listed  on the  OMX  Nordic
Exchange in Stockholm. For more information go to www.biovitrum.com.